, 12:186 | Cite as

Clinical profile and long term follow up of children and adolescents with prolactinomas

  • Shrikrishna V. Acharya
  • Raju A. Gopal
  • Tushar R. Bandgar
  • Shashank R. Joshi
  • Padma S. Menon
  • Nalini S. Shah


We report clinical presentation, response to medical treatment, and long-term follow-up of 39 children and adolescents with prolactinoma (F:M; 30:9) (30 macro and 9 microadenoma) diagnosed at the age of 9–20 years. Mean duration of follow up was 56 months. All patients were treated with bromocriptine (BC) at doses ranging from 2.5 to 20 mg/day or by cabergoline at doses ranging from 0.5 to 2 mg/week orally. Two patients received external conventional radiotherapy after surgery. In patients with macroprolactinoma (F:M; 21:9), headache and/or visual defects were the first symptoms. All females had primary or secondary amenorrhea. Growth arrest was not observed in any patient and pubertal development was appropriate for their age. Spontaneous or provocative galactorrhea was observed in 23 patients (all females) and none of male patient had gynecomastia. Mean serum prolactin (PRL) concentration at the time of diagnosis was 322.50 ng/ml in patients with microadenoma, 522.38 ng/ml in patients with macroadenoma and 2,294.86 ng/ml in patients with macroadenoma with suprasellar extension. In 25 patients, BC normalized PRL levels and caused variable, but significant, tumor shrinkage. Cabergoline normalized PRL concentrations in 14 patients. Pregnancy occurred in 6 patients while on treatment. Pregnancies were uncomplicated, and the patients delivered normal newborns at term. Impairment of other pituitary hormone secretion was documented at the time of diagnosis in only one patient. Postoperatively six patients had other pituitary hormone deficiencies. In conclusion, the medical treatment with dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation of the anterior pituitary function.


Prolactinoma Cabergoline Bromocryptine Radiotherapy Amenorrhea 


  1. 1.
    Davis CH, Odom GL, Woodhall B (1956) Brain tumors in children; clinical analysis of 164 cases. Pediatrics 18:856–870PubMedGoogle Scholar
  2. 2.
    Mindermann T, Wilson CB (1995) Pediatric pituitary adenomas. Neurosurgery 36:259–268. discussion, 269. doi: 10.1097/00006123-199502000-00004 PubMedCrossRefGoogle Scholar
  3. 3.
    Sano K (1987) Problems in the treatment of children with brain tumors. Prog Exp Tumor Res 30:1–9PubMedGoogle Scholar
  4. 4.
    Ludecke DK, Herrmann HD, Schulte FJ (1987) Special problems with neurosurgical treatments of hormone-secreting pituitary adenomas in children. Prog Exp Tumor Res 30:362–370PubMedGoogle Scholar
  5. 5.
    Laws ER, Scheithauer BW, Groover RV (1987) Pituitary adenomas in childhood and adolescence. Prog Exp Tumor Res 30:359–361PubMedGoogle Scholar
  6. 6.
    Colao A (2004) Pituitary tumors in childhood. In: New MI (ed) Pediatric endocrinology, Chap. 3.
  7. 7.
    Partington MD, Davis DH, Laws ER Jr, Scheithauer BW (1994) Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 80:209–216PubMedCrossRefGoogle Scholar
  8. 8.
    Haddad SF, VanGilder JC, Menezes AH (1991) Pediatric pituitary tumors. Neurosurgery 29:509–514. doi: 10.1097/00006123-199110000-00004 PubMedCrossRefGoogle Scholar
  9. 9.
    Lafferty AR, Chrousos GP (1999) Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 84:4317–4323. doi: 10.1210/jc.84.12.4317 PubMedCrossRefGoogle Scholar
  10. 10.
    Blackwell RE, Younger BJ (1986) Long-term medical therapy and follow up of pediatric adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 45:713–716PubMedGoogle Scholar
  11. 11.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G (1998) Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777–2780. doi: 10.1210/jc.83.8.2777 PubMedCrossRefGoogle Scholar
  12. 12.
    Fideleff HL, Boquete HR, Sequera A, Suárez M, Sobrado P, Giaccio A (2000) Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Ped Endocrinol Metab 13:261–267Google Scholar
  13. 13.
    Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325–331. doi: 10.1530/eje.0.1480325 PubMedCrossRefGoogle Scholar
  14. 14.
    Cannavo S, Venturino M, Curto L, De Menis E, D’Arrigo C, Tita P, Billeci D, Trimarchi F (2003) Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf) 58:519–527. doi: 10.1046/j.1365-2265.2003.01748.x CrossRefGoogle Scholar
  15. 15.
    Howlett TA, Wass JAH, Grossman A et al (1989) Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol (Oxf) 30:131–140. doi: 10.1111/j.1365-2265.1989.tb03734.x CrossRefGoogle Scholar
  16. 16.
    Tyson D, Reggiardo D, Sklar C, David R (1993) Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 147:1057–1061PubMedGoogle Scholar
  17. 17.
    Duntas LH (2001) Prolactinomas in children and adolescents—consequences in adult life. J Pediatr Endocrinol Metab 14(suppl 5):1227–1232 discussion, 1261–1262PubMedGoogle Scholar
  18. 18.
    George LD, Nicolau N, Scanlon MF, Davies JS (2000) Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin Endocrinol (Oxf) 53:595–599. doi: 10.1046/j.1365-2265.2000.01137.x CrossRefGoogle Scholar
  19. 19.
    Molitch ME, Thorner MO, Wilson C (1997) Management of prolactinomas. J Clin Endocrinol Metab 82:996–1000. doi: 10.1210/jc.82.4.996 PubMedCrossRefGoogle Scholar
  20. 20.
    Webster J, Piscitelli G, Polli A et al (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 331:904–909. doi: 10.1056/NEJM199410063311403 PubMedCrossRefGoogle Scholar
  21. 21.
    Biller BMK, Molitch ME, Vance ML et al (1996) Treatment of prolactinsecreting macroadenoma with once-a week dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343. doi: 10.1210/jc.81.6.2338 PubMedCrossRefGoogle Scholar
  22. 22.
    Colao A, Di Sarno A, Landi ML et al (1997) Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:876–883. doi: 10.1210/jc.82.3.876 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Shrikrishna V. Acharya
    • 1
  • Raju A. Gopal
    • 1
  • Tushar R. Bandgar
    • 1
  • Shashank R. Joshi
    • 1
  • Padma S. Menon
    • 1
  • Nalini S. Shah
    • 2
  1. 1.K E M HospitalMumbaiIndia
  2. 2.Department of EndocrinologyK E M HospitalMumbaiIndia

Personalised recommendations